Journals International Journal of Antim...

International Journal of Antimicrobial Agents
Tommaso Cai, Paolo Verze, Davide Arcaniolo, Savio Domenico Pandolfo, Francesco Smarrazzo, Celeste Mandredi, Carlo Tascini, Patrizio Caciagli, Massimiliano Lanzafame, Marco De Sio, Florian Wagenlehner, Truls E Bjerklund Johansen, Alessandro Palmieri
OBJECTIVES: To report the resistance rate against fosfomycin trometamol among outpatient women with symptoms related to UTI during a 6 years-period in a multicentre cross-sectional study. METHODS: Urinary samples were collected from three high volume laboratories from January 2015 to December 2020. The pattern of resistance to fosfomycin was analysed by using the Vitek II automated system. RESULTS: During the study period 7,289 urinary samples were collected and 8,321 strains were analysed...
September 20, 2023: International Journal of Antimicrobial Agents
Sanjay Singh, Tawanda Gumbo, Jann-Willem Alffenaar, Gunavanthi D Boorgula, Tania A Thomas, Keertan Dheda, Lesibana Malinga, Prithvi Raj, Santosh Aryal, Shashikant Srivastava
BACKGROUND: . To identify alternative treatment regimens for multi-drug resistant tuberculosis (MDR-TB), we tested meropenem in combination with β-lactamase inhibitors (BLIs) and other drugs. METHODS: . We performed (1) MIC experiments, (2) static time-kill studies (STKs) with different BLIs, and (3) a hollow fiber model system of TB (HFS-TB) study with meropenem-vaborbactam combined with human equivalent daily doses of 20mg/kg or 35mg/kg rifampin, or moxifloxacin 400mg, or linezolid 600mg versus the bedaquiline-pretonamid-linezolid (BPaL) for MDR-TB...
September 17, 2023: International Journal of Antimicrobial Agents
Rosa Fernández-Fernández, Carmen Lozano, Rocío Fernández-Pérez, Myriam Zarazaga, Andreas Peschel, Bernhard Krismer, Carmen Torres
Bacteriocins (of different origins) have been proposed as promising alternatives to face antimicrobial resistance-associated health problem. Isolates of the genus Staphylococcus are well-known bacteriocin producers, especially coagulase-negative species. Twenty-eight bacteriocin-producing staphylococcal isolates were selected from a previous study for an in-depth characterization. The antimicrobial activities (AA) of the producing isolates were studied by the Spot-on-lawn method and their crude cell-free-supernatants (CFS) and butanol extracts (BT) were evaluated by agar-diffusion assays against six indicator bacteria, including multidrug-resistant and zoonotic isolates (such as Listeria monocytogenes or methicillin-resistant Staphylococcus aureus [MRSA])...
September 14, 2023: International Journal of Antimicrobial Agents
Yu Ri Kang, Doo Ryeon Chung, Jae-Hoon Ko, Kyungmin Huh, Sun Young Cho, Cheol-In Kang, Kyong Ran Peck
BACKGROUND: There are many reports on gene mutations observed in methicillin-resistant Staphylococcus aureus (MRSA) showing reduced susceptibility to vancomycin. However, there are limited studies on the genetic alterations that contribute to high vancomycin minimum inhibitory concentration (MIC) in methicillin-susceptible S. aureus (MSSA). This study aimed to compare MSSA strains with high vancomycin MIC to those with low MIC and identify specific genetic alterations associated with increased vancomycin MIC...
September 14, 2023: International Journal of Antimicrobial Agents
Eline Hermans, Mathias Devreese, Markus Zeitlinger, Evelyn Dhont, Nick Verougstraete, Roos Colman, Johan Vande Walle, Peter De Paepe, Pieter A De Cock
OBJECTIVES: Knowledge on the tissue penetration of piperacillin-tazobactam in septic children is lacking. In this study, the feasibility and performance of microdialysis experiments were explored in septic piglets and children as part of a translational research project. METHODS: Multiple-day microdialysis investigations were performed in muscle tissue of twenty-two (of which eleven were septic) piglets and six septic children. An in vitro experiment preceded the (pre)clinical trials to derive optimal experimental settings and calibration technique...
September 14, 2023: International Journal of Antimicrobial Agents
Anna Olsson, Lisa Allander, Ayda Shams, Hissa Al-Farsi, Pernilla Lagerbäck, Thomas Tängdén
Combination therapy can enhance the activity of available antibiotics against multidrug-resistant Gram-negative bacteria. This study assessed the effects of polymyxin B combinations against carbapenemase-producing Klebsiella pneumoniae. Twenty clinical K. pneumoniae strains producing NDM-1 (n=8), OXA-48-like (n=10), or both NDM-1 and OXA-48-like (n=2) carbapenemases were used. Whole-genome sequencing was applied to detect resistance genes (e.g., encoding antibiotic-degrading enzymes) and sequence alterations influencing permeability or efflux...
September 14, 2023: International Journal of Antimicrobial Agents
Chungsoo Kim, Young Hwa Choi, Jung Yoon Choi, Hee Jung Choi, Rae Woong Park, Sandy Jeong Rhie
BACKGROUND: Prediction of antibiotic non-susceptibility based on patient characteristics and clinical status may support to select empiric antibiotics for suspected hospital-acquired urinary tract infections (HA-UTIs). METHODS: Prediction models were developed to predict non-susceptible results of eight antibiotics susceptibility tests ordered for suspected HA-UTI. Eligible patients were those with urine culture and susceptibility test results after 48 hours of admissions between 2010 and 2021...
September 14, 2023: International Journal of Antimicrobial Agents
Jia-Wen Wu, Tran Lam Tu Quyen, Yu-Chia Hsieh, Yi-Yin Chen, Lii-Tzu Wu, Yi-Jiun Pan
The emergence of carbapenem-resistant Klebsiella pneumoniae (CRKP) is related to the transmission of carbapenemase genes. Strains carrying more than one carbapenemase with a broadened spectrum of antibiotic resistance have been detected, which is concerning. Although blaKPC -encoding ST11-KL47/KL64 strains are dominant, other clones are emerging. Here, we investigated 137 CRKP from patients' blood samples in Taiwan. Polymerase chain reaction (PCR) was used to identify carbapenemase genes and capsular (KL-)types...
September 4, 2023: International Journal of Antimicrobial Agents
Shigang Yao, Xinyi Wu, Yi Li, Yuqin Song, Chao Wang, Gang Zhang, Jie Feng
The rapid emergence of infections caused by MDR Acinetobacter baumannii poses a serious threat to global public health. Therefore, it has become important to obtain a deeper understanding of the mechanisms of multidrug resistance and pathogenesis of A. baumannii. However, there are still relatively few genetic engineering tools for A. baumannii. Although A. baumannii possesses Type I-F CRISPR-Cas systems, they have not yet been used for genetic modifications. Here, we developed a single plasmid-mediated native Type I-F CRISPR-Cas system for gene editing and gene regulation in A...
September 4, 2023: International Journal of Antimicrobial Agents
Xiaoyu Lu, Lifei Zhang, Kai Peng, Qiaojun Wang, Ruoqi Liu, Zhiqiang Wang, Ruichao Li
The emergence of pathogens resistant to both tigecycline and carbapenem poses a threat to public health globally. Continuous emergence of novel tet(X) variants accelerates the tigecycline resistance crisis. In this study, we first identified the tigecycline resistance gene tet(X22) and characterized the coexistence of tet(X22) with carbapenem resistance gene blaNDM-1 in Pseudomonas caeni, which was a novel species defined in 2009. The carbapenem- and tigecycline-resistant P. caeni isolate CE14 was obtained from chicken feces in 2022...
September 2, 2023: International Journal of Antimicrobial Agents
Kuang-Yao Chen, Chien-Ju Cheng, Yi-Ju Chen, Cheng-Hsun Chiu, Lian-Chen Wang
Angiostrongylus cantonensis, which is also known as rat lungworm, is an important food-borne zoonotic parasite that causes severe neuropathological damage and symptoms, including eosinophilic meningitis and eosinophilic meningoencephalitis, in humans. At present, the therapeutic strategy for cerebral angiostrongyliasis remains controversial. Benzaldehyde, an important bioactive constituent of Gastrodia elata (Tianma) reduces oxidative stress by inhibiting ROS production. This study aimed to evaluate the therapeutic effect of benzaldehyde in combination with albendazole on angiostrongyliasis in animal models...
September 2, 2023: International Journal of Antimicrobial Agents
Sung-Woon Kang, Somi Park, Areum Kim, Jaijun Han, Jiyoung Lee, Hyeonji Seo, Heungsup Sung, Mi-Na Kim, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Eun Hee Song, Yong Pil Chong
BACKGROUND: The rise of carbapenemase-producing Enterobacterales (CPE) has become a major concern due to its high mortality and the limited treatment options. This study aimed to evaluate the incidence and characteristics of subsequent CPE bacteremia in rectal CPE carriers and to investigate the risk factors for CPE bacteremia compared with non-carbapenemase-producing (non-CP) Enterobacterales bacteremia. METHODS: A retrospective analysis was conducted on adult patients who were confirmed to have CPE colonization by stool surveillance culture at a tertiary hospital from January 2018 to February 2022...
August 24, 2023: International Journal of Antimicrobial Agents
Eric Senneville, Guillermo Cuervo, Matthieu Gregoire, Carmen Hidalgo-Tenorio, Francois Jehl, Jose M Miro, R Andrew Seaton, Bo Söderquist, Alex Soriano, Florian Thalhammer, Federico Pea
BACKGROUND: Dalbavancin is a lipoglycopeptide with a long elimination half-life, currently licensed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. Dalbavancin's potential in treating off-label complex gram-positive infections is promising and real-world experience in treating such infections is growing. However, clear guidance on extended dosing regimens is lacking. OBJECTIVES: We aim to provide clear expert opinion based on recent pharmacokinetic literature and expert and real-world experience in infection areas that require >2 weeks of treatment...
August 24, 2023: International Journal of Antimicrobial Agents
Erin Chung, Winnie Seto
BACKGROUND: Neonatal sepsis is commonly treated with vancomycin in the neonatal intensive care unit (NICU). Therapeutic drug monitoring (TDM) of vancomycin is routinely used to personalize dosing to optimize effectiveness and avoid toxicity. This study aimed to define a target range by evaluating associations between vancomycin trough concentrations or area-under-the-concentration-time-curve over 24 hours (AUC24h ) and clinical outcomes in neonates. METHODS: Neonates, who were admitted to the NICU receiving vancomycin intravenously, were included in this retrospective cohort study...
August 24, 2023: International Journal of Antimicrobial Agents
Brent Nishimura, Jenny Escalante, Vyanka Mezcord, Marisel R Tuttobene, Tomás Subils, Luis A Actis, Fernando Pasteran, Marcelo E Tolmasky, Robert A Bonomo, María Soledad Ramirez
No abstract text is available yet for this article.
August 17, 2023: International Journal of Antimicrobial Agents
Sang-Min Oh, Ja Min Byun, Chan Mi Lee, Chang Kyung Kang, Dong-Yeop Shin, Youngil Koh, Junshik Hong, Pyoeng Gyun Choe, Wan Beom Park, Nam Joong Kim, Sung-Soo Yoon, Inho Kim, Myoung-Don Oh
INTRODUCTION: To critically re-evaluate the necessity of routine empirical antifungal therapy in prolonged febrile neutropenia (FN) in acute myelogenous leukemia (AML) in the current era of antimold prophylaxis, we compared clinical outcomes in such patients who were treated with either empirical or preemptive antifungal therapy. METHODS: We retrospectively reviewed adult AML patients (aged ≥ 18 years) who received antimold prophylaxis and developed FN for ≥ 4 days during induction or re-induction chemotherapy at a single center between September 2016 and December 2020...
August 16, 2023: International Journal of Antimicrobial Agents
Thi Van Anh Nguyen, Quang Huy Nguyen, Tran Nam Tien Nguyen, Richard M Anthony, Dinh Hoa Vu, Jan-Willem C Alffenaar
Pretomanid (PA-824), a novel anti-tuberculosis nitroimidazoxazine, has been approved for multidrug-resistant tuberculosis treatment for a few years. Pretomanid has been demonstrated to be highly active against Mycobacterium tuberculosis when combined with other anti-tuberculosis drugs. This review provides an update of the current knowledge on the modes of action, resistance mechanisms, emergence of drug resistance, status of antimicrobial susceptibility testing for pretomanid and their relevance for clinical practice...
August 16, 2023: International Journal of Antimicrobial Agents
Jon Salmanton-García, Francesco Marchesi, Philipp Koehler, Barbora Weinbergerová, Natasa Čolović, Iker Falces-Romero, Caterina Buquicchio, Francesca Farina, Jens VAN Praet, Monika M Biernat, Federico Itri, Lucia Prezioso, Carlo Tascini, Antonio Vena, Alessandra Romano, Mario Delia, Julio Dávila-Valls, Sonia Martín-Pérez, Esperanza Lavilla-Rubira, Tatjana Adžić-Vukičević, Daniel García-Bordallo, Alberto López-García, Mariana Criscuolo, Verena Petzer, Nicola S Fracchiolla, Ildefonso Espigado, Uluhan Sili, Stef Meers, Nurettin Erben, Chiara Cattaneo, Athanasios Tragiannidis, Eleni Gavriilaki, Martin Schönlein, Mirjana Mitrovic, Nikola Pantic, Maria Merelli, Jorge Labrador, José-Ángel Hernández-Rivas, Andreas Glenthøj, Guillemette Fouquet, Maria Ilaria Del Principe, Michelina Dargenio, María Calbacho, Caroline Besson, Milena Kohn, Stefanie Gräfe, Ditte Stampe Hersby, Elena Arellano, Gökçe MelisÇOLAK, Dominik Wolf, Monia Marchetti, Anna Nordlander, Ola Blennow, Raul Cordoba, Bojana Mišković, Miloš Mladenović, Martina Bavastro, Alessandro Limongelli, Laman Rahimli, Livio Pagano, Oliver A Cornely
INTRODUCTION: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, while molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir, because it displays less frequent drug-drug interactions and contraindications. A caveat connected to molnupiravir derives from the mode of action inducing viral mutations...
August 13, 2023: International Journal of Antimicrobial Agents
Subhankar Mukhopadhyay, Pengfei Zhang, Kenneth K W To, Yannan Liu, Changqing Bai, Sharon S Y Leung
Bacteriophage (phage) therapy, exploiting phage which are the natural enemies of bacteria, has been reintroduced to treat multidrug-resistant (MDR) bacterial infections. However, some intrinsic drawbacks of phage are overshadowing its clinical uses, particularly the narrow host spectrum and rapid emergence of resistance upon treatment. The use of phage and antibiotic combination exhibiting synergistic bacterial killing (termed phage-antibiotic synergy or PAS) has therefore been proposed. It is well-reported that the types and doses of phage and antibiotic are critical in achieving PAS...
August 11, 2023: International Journal of Antimicrobial Agents
Qian Liu, Sanwang Li, Feifan Xie
The altered pharmacokinetics (PK) of linezolid are pronounced in critically ill patients undergoing different modalities of renal replacement therapy (RRT). This study aimed to provide a pooled population PK analysis of linezolid in patients undergoing RRT, and to evaluate the pharmacodynamic target attainment of linezolid standard dosing (600 mg q12h). In total, 414 pooled linezolid concentration observations from 69 patients undergoing intermittent haemodialysis (IHD), sustained low-efficiency dialysis (SLED) or continuous RRT were used to develop the population PK model...
August 11, 2023: International Journal of Antimicrobial Agents
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.